MX2021015508A - Pyridine carbamates and their use as glun2b receptor modulators. - Google Patents
Pyridine carbamates and their use as glun2b receptor modulators.Info
- Publication number
- MX2021015508A MX2021015508A MX2021015508A MX2021015508A MX2021015508A MX 2021015508 A MX2021015508 A MX 2021015508A MX 2021015508 A MX2021015508 A MX 2021015508A MX 2021015508 A MX2021015508 A MX 2021015508A MX 2021015508 A MX2021015508 A MX 2021015508A
- Authority
- MX
- Mexico
- Prior art keywords
- carbamates
- pyridine
- receptor modulators
- glun2b
- pyridine carbamates
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Abstract
Pyridine carbamates, pharmaceutical compositions containing pyridine carbamates, and uses of the pyridine carbamates and pharmaceutical compositions for modulating GluN2B receptors and for treating diseases, disorders, and medical conditions mediated by GluN2B receptor activity.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962861634P | 2019-06-14 | 2019-06-14 | |
PCT/EP2020/066400 WO2020249799A1 (en) | 2019-06-14 | 2020-06-12 | Pyridine carbamates and their use as glun2b receptor modulators |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021015508A true MX2021015508A (en) | 2022-01-31 |
Family
ID=71120147
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021015508A MX2021015508A (en) | 2019-06-14 | 2020-06-12 | Pyridine carbamates and their use as glun2b receptor modulators. |
Country Status (10)
Country | Link |
---|---|
US (1) | US11447503B2 (en) |
EP (1) | EP3983074A1 (en) |
JP (1) | JP2022538774A (en) |
KR (1) | KR20220020916A (en) |
CN (1) | CN114007691A (en) |
AU (1) | AU2020293584A1 (en) |
BR (1) | BR112021025132A2 (en) |
CA (1) | CA3143103A1 (en) |
MX (1) | MX2021015508A (en) |
WO (1) | WO2020249799A1 (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW201819376A (en) | 2016-10-06 | 2018-06-01 | 比利時商健生藥品公司 | Substituted 1H-imidazo[4,5-b]pyridin-2(3H)-ones and their use as GLUN2B receptor modulators |
AU2020293642A1 (en) | 2019-06-14 | 2022-01-20 | Janssen Pharmaceutica Nv | Substituted pyrazolo[4,3-b]pyridines and their use as GluN2B receptor modulators |
WO2020249796A1 (en) | 2019-06-14 | 2020-12-17 | Janssen Pharmaceutica Nv | Pyrazine carbamates and their use as glun2b receptor modulators |
AU2020292994A1 (en) | 2019-06-14 | 2022-01-06 | Janssen Pharmaceutica Nv | Substituted pyrazolo-pyrazines and their use as GluN2B receptor modulators |
US11530210B2 (en) | 2019-06-14 | 2022-12-20 | Janssen Pharmaceutica Nv | Substituted heteroaromatic pyrazolo-pyridines and their use as GLUN2B receptor modulators |
KR20220020916A (en) | 2019-06-14 | 2022-02-21 | 얀센 파마슈티카 엔.브이. | Pyridine carbamates and their use as GluN2B receptor modulators |
CR20210580A (en) | 2019-06-14 | 2022-01-31 | Janssen Pharmaceutica Nv | Substituted pyrazolo-pyridine amides and their use as glun2b receptor modulators |
AU2022328310A1 (en) * | 2021-08-09 | 2024-03-28 | Janssen Pharmaceutica Nv | Monoacylglycerol lipase modulators for use in autism spectrum disorders |
Family Cites Families (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4980357A (en) | 1990-03-01 | 1990-12-25 | Pfizer Inc. | Azolidinedione derivatives |
GB9407447D0 (en) | 1994-04-14 | 1994-06-08 | Glaxo Group Ltd | Chemical compounds |
WO1998004534A1 (en) | 1996-07-31 | 1998-02-05 | Nikken Chemicals Co., Ltd. | 6-phenyltetrahydro-1,3-oxazin-2-one derivatives and medicinal compositions containing the same |
WO2002000629A1 (en) | 2000-06-26 | 2002-01-03 | Merck & Co., Inc. | Iminopyrimidine nmda nr2b receptor antagonists |
US6610723B2 (en) | 2001-01-29 | 2003-08-26 | Hoffmann-La Roche Inc. | Imidazole derivatives |
CN100368411C (en) | 2002-03-28 | 2008-02-13 | 卫材R&D管理有限公司 | 7-azaindoles as inhibitors of c-Jun N-terminal kinases for the treatment of neurodegenerative disorders |
US7005432B2 (en) | 2002-05-16 | 2006-02-28 | Hoffman-La Roche Inc. | Substituted imidazol-pyridazine derivatives |
IL164209A0 (en) | 2002-05-31 | 2005-12-18 | Eisai Co Ltd | Pyrazole derivatives and pharmaceutical compositions containing the same |
CN101018779A (en) | 2004-02-18 | 2007-08-15 | 阿斯利康(瑞典)有限公司 | Triazole compounds and their use as metabotropic glutamate receptor antagonists |
JP2008538544A (en) | 2004-09-23 | 2008-10-30 | レディ ユーエス セラピューティックス, インコーポレイテッド | Novel pyrimidine compounds, processes for their preparation and compositions containing them |
WO2007115231A2 (en) | 2006-03-30 | 2007-10-11 | Chemocentryx, Inc. | Cxcr4 modulators |
PE20090717A1 (en) | 2007-05-18 | 2009-07-18 | Smithkline Beecham Corp | QUINOLINE DERIVATIVES AS PI3 KINASE INHIBITORS |
RU2479577C2 (en) | 2007-05-25 | 2013-04-20 | Эбботт Гмбх Унд Ко.Кг | Heterocyclic compounds as positive modulators of metabotropic glutamate receptor 2 (mglu2 receptor) |
WO2009004430A1 (en) * | 2007-06-29 | 2009-01-08 | Pfizer Inc. | N-benzyl oxazolidinones and related heterocycleic compounds as potentiators of glutamate receptors |
CL2008002521A1 (en) | 2007-08-30 | 2009-11-20 | Takeda Pharmaceuticals Co | Substituted pyrazole derivative compounds, androgen receptor antagonist; pharmaceutical composition comprising said compounds; and use of the compound for the treatment of cancer. |
US20100249164A1 (en) | 2007-10-31 | 2010-09-30 | Renger John J | Modulation of sleep with nr2b receptor antagonists |
RU2499598C2 (en) | 2008-03-27 | 2013-11-27 | Евотек Интернациональ Гмбх | Method of treating disorders using selective nr2b subtype nmda receptor antagonist |
WO2009157196A1 (en) | 2008-06-25 | 2009-12-30 | 武田薬品工業株式会社 | Amide compound |
MX2011001019A (en) | 2008-08-05 | 2011-03-25 | Daiichi Sankyo Co Ltd | Imidazopyridin-2-on derivative. |
US9643922B2 (en) | 2008-08-18 | 2017-05-09 | Yale University | MIF modulators |
MX2011003691A (en) | 2008-10-16 | 2011-09-06 | Ortho Mcneil Janssen Pharm | Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors. |
EP2379561B1 (en) | 2008-11-25 | 2015-11-04 | University Of Rochester | Mlk inhibitors and methods of use |
US8969342B2 (en) | 2009-03-20 | 2015-03-03 | Brandeis University | Compounds and methods for treating mammalian gastrointestinal microbial infections |
US8906914B2 (en) | 2009-08-18 | 2014-12-09 | Janssen Pharmaceutica Nv | Ethylene diamine modulators of fatty acid hydrolase |
EP2579717A4 (en) | 2010-06-09 | 2013-12-11 | Merck Sharp & Dohme | Positive allosteric modulators of mglur2 |
JP5990106B2 (en) | 2011-01-28 | 2016-09-07 | 佐藤製薬株式会社 | Fused ring compound |
JP2012188363A (en) | 2011-03-09 | 2012-10-04 | Dainippon Sumitomo Pharma Co Ltd | Azabenzoimidazolone derivative |
AR086254A1 (en) | 2011-05-26 | 2013-11-27 | Lilly Co Eli | USEFUL IMIDAZOL DERIVATIVES FOR THE TREATMENT OF ARTHRITIS |
PL2570415T3 (en) | 2011-09-19 | 2016-01-29 | Sanofi Sa | N-[4-(1H-Pyrazolo[3,4-b]pyrazin-6-yl)-phenyl]-sulfonamides and their use as pharmaceuticals |
WO2013060029A1 (en) | 2011-10-28 | 2013-05-02 | Merck Sharp & Dohme Corp | Allosteric modulators of metabotropic glutamate receptors |
US9434743B2 (en) | 2012-03-02 | 2016-09-06 | Takeda Pharmaceutical Company Limited | Indazole derivatives |
MA37975B2 (en) | 2012-09-11 | 2021-03-31 | Genzyme Corp | Glucosylceramide synthase inhibitors |
WO2014124651A1 (en) | 2013-02-15 | 2014-08-21 | Københavns Universitet | Pyrrolidine-2-carboxylic acid derivatives as iglur antagonists |
TW201444820A (en) | 2013-03-13 | 2014-12-01 | Abbvie Inc | Pyridine CDK9 kinase inhibitors |
RU2680100C9 (en) | 2013-03-15 | 2019-04-18 | Плексксикон Инк. | Heterocyclic compounds and uses thereof |
EP3674300B1 (en) | 2013-06-21 | 2022-10-12 | Zenith Epigenetics Ltd. | Novel bicyclic bromodomain inhibitors |
CN105814057B (en) | 2013-07-31 | 2019-05-03 | 默克专利有限公司 | Pyrimidine, pyridine and pyrazine as BTK inhibitor and application thereof |
US9695168B2 (en) | 2014-07-10 | 2017-07-04 | Incyte Corporation | Substituted imidazo[1,5-α]pyridines and imidazo[1,5-α]pyrazines as LSD1 inhibitors |
PL3180315T3 (en) | 2014-08-15 | 2020-09-07 | Janssen Pharmaceuticals, Inc. | Pyrazoles |
PT3180329T (en) | 2014-08-15 | 2020-06-08 | Janssen Pharmaceuticals Inc | Triazoles as nr2b receptor inhibitors |
WO2016081649A1 (en) | 2014-11-18 | 2016-05-26 | Emory University | Thieno[2,3-d]pyrimidin-4-one derivatives as nmdar modulators and uses related thereto |
CN107406435A (en) | 2015-02-23 | 2017-11-28 | 百时美施贵宝公司 | The compound of new treatment hepatitis C |
MA41803A (en) | 2015-03-24 | 2018-01-30 | Almirall Sa | AMINO-INDAZOLES USED AS SODIUM CHANNEL INHIBITORS |
WO2017007938A1 (en) | 2015-07-09 | 2017-01-12 | Janssen Pharmaceutica Nv | Substituted 4-azaindoles and their use as glun2b receptor modulators |
MX2018009752A (en) | 2016-02-10 | 2019-02-07 | Janssen Pharmaceutica Nv | Substituted 1,2,3-triazoles as nr2b-selective nmda modulators. |
TW201819376A (en) | 2016-10-06 | 2018-06-01 | 比利時商健生藥品公司 | Substituted 1H-imidazo[4,5-b]pyridin-2(3H)-ones and their use as GLUN2B receptor modulators |
BR112019026478A2 (en) | 2017-06-14 | 2020-07-14 | Trevena, Inc. | compounds for modulating s1p1 activity and methods of using them |
JP7346441B2 (en) | 2018-04-04 | 2023-09-19 | ヤンセン ファーマシューティカ エヌ.ベー. | Substituted pyridines and pyrimidines and their use as GLUN2B receptor modulators |
CN110294756A (en) | 2019-06-04 | 2019-10-01 | 广州市原子高科同位素医药有限公司 | GluN2B subunit targeting type central nervous system positive electron tracer and its preparation |
AU2020293642A1 (en) | 2019-06-14 | 2022-01-20 | Janssen Pharmaceutica Nv | Substituted pyrazolo[4,3-b]pyridines and their use as GluN2B receptor modulators |
WO2020249796A1 (en) | 2019-06-14 | 2020-12-17 | Janssen Pharmaceutica Nv | Pyrazine carbamates and their use as glun2b receptor modulators |
AU2020292994A1 (en) | 2019-06-14 | 2022-01-06 | Janssen Pharmaceutica Nv | Substituted pyrazolo-pyrazines and their use as GluN2B receptor modulators |
US11530210B2 (en) | 2019-06-14 | 2022-12-20 | Janssen Pharmaceutica Nv | Substituted heteroaromatic pyrazolo-pyridines and their use as GLUN2B receptor modulators |
CR20210580A (en) | 2019-06-14 | 2022-01-31 | Janssen Pharmaceutica Nv | Substituted pyrazolo-pyridine amides and their use as glun2b receptor modulators |
KR20220020916A (en) | 2019-06-14 | 2022-02-21 | 얀센 파마슈티카 엔.브이. | Pyridine carbamates and their use as GluN2B receptor modulators |
-
2020
- 2020-06-12 KR KR1020227001091A patent/KR20220020916A/en unknown
- 2020-06-12 BR BR112021025132A patent/BR112021025132A2/en unknown
- 2020-06-12 US US16/899,809 patent/US11447503B2/en active Active
- 2020-06-12 WO PCT/EP2020/066400 patent/WO2020249799A1/en unknown
- 2020-06-12 AU AU2020293584A patent/AU2020293584A1/en active Pending
- 2020-06-12 MX MX2021015508A patent/MX2021015508A/en unknown
- 2020-06-12 CA CA3143103A patent/CA3143103A1/en active Pending
- 2020-06-12 JP JP2021573608A patent/JP2022538774A/en not_active Withdrawn
- 2020-06-12 EP EP20734123.1A patent/EP3983074A1/en active Pending
- 2020-06-12 CN CN202080043610.3A patent/CN114007691A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2022538774A (en) | 2022-09-06 |
US11447503B2 (en) | 2022-09-20 |
CA3143103A1 (en) | 2020-12-17 |
CN114007691A (en) | 2022-02-01 |
AU2020293584A1 (en) | 2022-01-20 |
WO2020249799A1 (en) | 2020-12-17 |
US20200392154A1 (en) | 2020-12-17 |
BR112021025132A2 (en) | 2022-01-25 |
EP3983074A1 (en) | 2022-04-20 |
KR20220020916A (en) | 2022-02-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021015508A (en) | Pyridine carbamates and their use as glun2b receptor modulators. | |
MX2021015511A (en) | Pyrazine carbamates and their use as glun2b receptor modulators. | |
PH12019502058A1 (en) | Farnesoid x receptor agonists and uses thereof | |
BR112021021754A2 (en) | Substituted cycloalkyls as modulators of the integrated stress pathway | |
MX2021005887A (en) | 2-formyl-3-hydroxyphenyloxymethyl compounds capable of modulating hemoglobin. | |
MX2021015500A (en) | Substituted pyrazolo-pyrazines and their use as glun2b receptor modulators. | |
NZ750174A (en) | Somatostatin modulators and uses thereof | |
NZ757081A (en) | Somatostatin modulators and uses thereof | |
NZ737399A (en) | Ccr2 modulators | |
CR20210615A (en) | Substituted heteroaromatic pyrazolo-pyridines and their use as glun2b receptor modulators | |
JOP20210328A1 (en) | Substituted pyrazolo-pyridine amides and their use as glun2b receptor modulators | |
PH12021550605A1 (en) | Farnesoid x receptor agonists and uses thereof | |
MX2020013085A (en) | Melanocortin subtype-2 receptor (mc2r) antagonists and uses thereof. | |
MX2022001874A (en) | Nonpeptide somatostatin type 5 receptor agonists and uses thereof. | |
MX2018000352A (en) | Substituted 4-azaindoles and their use as glun2b receptor modulators. | |
MX2020007586A (en) | Process of making somatostatin modulators. | |
MX2019006877A (en) | 4 - pregenen- 11ss - 17 - 21 -triol-3, 20 -dione derivatives for the treatment of ocular conditions. | |
MX2023000677A (en) | Estrogen receptor-modulating compounds. | |
MX2021011008A (en) | Fused piperidinyl bicyclic and related compounds as modulators of c5a receptor. | |
MX2022011310A (en) | Azabicyclo and diazepine derivatives for treating ocular disorders. | |
MX2020009459A (en) | Spirocyclic ror-gamma modulators. | |
MX2022007439A (en) | Gem-disubstituted piperidine melanocortin subtype-2 receptor (mc2r) antagonists and uses thereof. | |
MX2022000520A (en) | Estrogen receptor-modulating compounds. | |
CR20220072A (en) | Pyridine derivatives as tmem16a modulators for use in the treatment of respiratory conditions | |
EA201992051A1 (en) | FARNESOID X-RECEPTOR AGONISTS AND THEIR APPLICATION |